Biolegend, 636454, Ultra-LEAF™ Purified anti-human FGF-9 Antibody, 1mg

FGF-9, member of the fibroblast growth factor family, is a potent mitogen and can stimulate proliferation and invasion capacity of epithelial cells. Expressed in lung mesothelium and epithelium, FGF-9 plays an important role in lung development and maintenance in the adult organ. FGF-9 regulates lung branching by stimulating mesenchymal proliferation and inducing FGF-10 expression in the mesenchyme. FGF-9 deficient mice exhibit severely impaired lung development that may cause perinatal death. Additional phenotypes of FGF-9 deficient mice may include testicular hypoplasia and male-to-female sex reversion. Additional studies in mice have demonstrated that FGF-9 is required for normal sex determination by maintaining SOX9 expression and regulation of testosterone production in the mouse Leydig cells through AKT and MAPK signaling pathways. FGF-9 can be detected in the central nervous system and promotes the differentiation and survival of both neurons and glia cells. FGF-9 also regulates gap-junction formation in cultured astroglial cells. FGF-9 is also involved in bone formation, retinal differentiation and maturation, wound healing, and maintaining the stemness of kidney nephron progenitors. Expression of FGF-9 can be transcriptionally induced by prostaglandin E2, estrogen, and hypoxia. It has been shown that FGF-9 can form dimers and the dimeric FGF-9 binds to heparin with a higher affinity than the monomeric FGF-9. Overexpression of FGF-9 has been associated with many human cancers such as ovarian endometrioid adenocarcinomas, glioma, prostate cancer, and endometriosis.
1mg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant human FGF-9
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/μg of the protein (< 0.001 ng/μg of the protein) as determined by the LAL test
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Neut - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by neutralizing the proliferation of NIH3T3 cells induced by recombinant human FGF-9 (Cat. No. 558702) at 5 ng/mL. ND50 range: 0.08 - 0.8 μg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_3699066 (BioLegend Cat. No. 636453)
Structure: Growth factor
Distribution: Expression of FGF-9 has been reported in lung, γδ T cells, central nervous systems, the epithelium of tooth germs, and the prostate epithelium
Function: FGF-9 is involved in embryonic development and many biological functions at adulthood. FGF-9 is induced by PGE2.
Interaction: Leydig cells, intestinal mesenchymal stem cells, lung mesenchymal cells, cranial mesenchymal cells, glial cells, fibroblasts, and epithelial cells
Ligand/Receptor: FGF-9 binds and activates the IIIc isoforms of FGFR1, FGFR2, and FGFR3 and the IIIb isoform of FGFR3.
Cell Type: Embryonic Stem Cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, Neural Stem Cells
Biology Area: Cell Biology, Neuroscience, Stem Cells, Synaptic Biology
Molecular Family: Cytokines/Chemokines, Growth Factors
Antigen References: Hendrix ND, et al. 2006. Cancer Res. 66:1354-62. Colvin JS, et al. 2001. Cell. 104:875-89. Colvin JS, et al. 2001. Development. 128:2095-106. Zhang X, et al. 2006. J Biol Chem. 281:15694-700. Gay D, et al. 2013. Nat Med. 7:916-23. Harada M, et al. 2009. Nat Genet. 41:289-98. Lai MS, et al. 2014. PLoS One. 9:e90243. Barak H, et al. 2012. Dev Cell. 22:1191-207. Santos-Ocampo S, et al. 1996. J Biol Chem. 271:1726-31. Geske M, et al. 2008. Development. 135:2959-68.
Gene ID: 2254
UniProt: View information about FGF-9 on UniProt.org
Clone: W20200C
Regulatory Status: RUO
Other Names: Fibroblast Growth Factor 9, Glia-Activating Factor (GAF), Heparin-Binding Growth Factor 9 (HBGF-9), HBFG-9, SYNS3
Isotype: Rat IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.